This trial is active, not recruiting.

Condition kidney transplant
Treatment rapamycin
Phase phase 4
Target mTOR
Sponsor Vanderbilt University
Start date June 2000
End date December 2008
Trial size 30 participants
Trial identifier NCT00223678, 000294


A study to determine the effect on renal function in renal transplant patients with biopsy proven CAN nephropathy who are switched from a CI triple drug regimen to a Rapamycin based triple drug regimen or maintained on their CI protocol

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
(Active Comparator)
pt will switch from calcineurin inhibitor (CYA, prgraf) to Rapamycin
rapamycin Sirolimus
Rapamycin will start within 24 hours of last calcineurin inhibitors (Cya, Prgraf). Initial dose of Rapamune 10mg will be given for 3 days and then dose will be adjusted to attain a target whole blood trough of 5-15
(No Intervention)
Patient will remain on calcineruin inhibitor

Primary Outcomes

graft survival
time frame: 3 years

Eligibility Criteria

Male or female participants at least 12 years old.

Inclusion Criteria: 1. Patient is the recipient of a cadaveric or living donor renal transplant. 2. Patient was > 12 years of age at the time of transplant. 3. Patient is at least 3 months post-transplant. 4. Patient has been on a calcineurin inhibitor based immunosuppression since the transplant. 5. Patient has one of the following risk factors for chronic renal allograft failure: I. Serum creatinine > 2.0 mg/dL 3 months or later post-transplant in males patients. II. Serum creatinine > 1.7 mg/dL 3 months or later post-transplant in female patients. III. Serum > 30% increased over post discharge nadir. 6. Patients had a renal biopsy that shows chronic allograft nephropathy. 7. Patient or legal guardian had signed and dated an IRB approved informed consent document and is willing and able to follow study procedures. 8. If female and of child bearing potential, patient has a negative pregnancy test and agrees to practice effective birth control while receiving mycophenolate mofetil (MMF), Rapamycin and other immunosuppressants. - Exclusion Criteria: 1. Patient is the recipient of a solid organ transplant other than the kidney. 2. Patient is dialysis dependent. 3. Patient has recurrence of primary renal disease, or de novo renal disease. 4. Patient has an estimated creatinine clearance <25ml/min calculated using the Crockcroft/Gault formula. 5. Patient has changed maintenance immunosuppressant therapy (e.g., azathioprine to MMF) within three months of randomization. 6. Baseline biopsy shows acute rejection Banff Grade > IIB. 7. Patient required anti-lymphocyte therapy to treat rejection found on baseline biopsy. 8. Patient has received an investigational immunosuppressant within three months. 9. Patient is pregnant or lactating. 10. Patient is a known carrier of any of the HIV viruses. 11. Patient has known hypersensitivity to Rapamycin, or any of the excipients of the drug.

Additional Information

Official title Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure
Principal investigator Anthony Langone, M.D.
Trial information was received from ClinicalTrials.gov and was last updated in February 2008.
Information provided to ClinicalTrials.gov by Vanderbilt University.